硬皮病治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

硬皮病治疗市场按疾病类型(系统性硬皮病和局部硬皮病)、药物类型和地理细分。

市场快照

Scleroderma Therapeutics-1
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.7 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

硬皮病是一种罕见的慢性疾病,影响全球约 250 万人。由于疾病流行率上升和制药公司专注于开发新药等因素,预计硬皮病治疗市场将在不久的将来增长。

  • 根据 Scleroderma & Raynaud's UK 的数据,在英国,2018 年约有 19,000 人被诊断出患有硬皮病。在英国,Scleroderma & Raynaud's UK 是唯一一家致力于改善该国硬皮病患者生活的慈善机构。研究表明,这种疾病在非裔美国人中的患病率更高,女性的患病率是男性的四到九倍。
  • 目前,硬皮病的治疗在控制并发症和缓解症状方面取得了进展。疾病修饰治疗正在广泛研究用于硬皮病,其旨在抑制组织纤维化以及血管和免疫系统改变,这是疾病发病机制的三个关键组成部分。 
  • 制药公司即将推出的疗法及其未来的批准可能会促进所研究市场的增长。

报告范围

硬皮病是一种影响皮肤、血管、肌肉和内脏器官的自身免疫性疾病。这种疾病通常是由于异常的免疫反应引起的。这种疾病的治疗包括免疫抑制药物,在某些情况下,糖皮质激素。

By Disease Type
Systemic Scleroderma
Localized Scleroderma
By Drug Type
Phosphodiesterase 5 inhibitors - PHA
Prostacyclin Analogues
Immunosuppressors
Endothelin Receptor Antagonists
Calcium Channel Blockers
Other Drug Types
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

预计免疫抑制剂在预测期内将出现高增长

硬皮病没有完全治愈的方法。然而,科学家们提出了一些对患有这种疾病的人有用的疗法。免疫抑制剂是一种有助于减轻硬皮病症状的药物。由于这种疾病与免疫系统有关,免疫抑制剂通过减少免疫反应的发生来帮助同样的疾病。免疫抑制剂的作用是触发免疫细胞的死亡或阻止更多免疫细胞的产生。免疫疗法的一个例子是利妥昔单抗,它降低了 B 细胞的水平,B 细胞是一种参与硬皮病的免疫细胞。

截至目前,免疫抑制剂尚未被 FDA 批准用于治疗硬皮病,但它们是在标签外给予患者的。用于硬皮病的一些免疫抑制剂包括甲氨蝶呤、CellCept、Cytoxan、Imuran、环孢菌素和胸腺球蛋白。目前正在进行几项临床试验以研究免疫抑制剂的功效,这些临床试验的结果表明免疫抑制剂可有益于治疗硬皮病。

因此,随着越来越多的临床试验和免疫抑制剂的有效性得到证实,所研究的市场预计将在未来出现增长。

img1

北美主导市场

预计北美将占据硬皮病治疗市场的最大份额。这主要归因于患有这些疾病的人数不断增加以及发达的医疗保健部门允许获得新的治疗方法。在美国,硬皮病基金会等组织一直致力于疾病管理和相关研究。根据该基金会,硬皮病影响美国约 300,000 人,约为千分之一。据观察,自过去十年以来,硬皮病在美国愈演愈烈,因此,该国一直在进行持续研究,以开发适合硬皮病的治疗方法。

Scleroderma Therapeutics-3

竞争格局

硬皮病治疗市场竞争适度,几家大型制药公司已参与市场研究。由于没有可用的治疗药物,这些公司一直在提供减轻疾病症状的药物。很少有公司的产品正在筹备中,也很少有公司寻求 FDA 的批准。随着这些公司越来越重视研发,预计新疗法可能会进入研究市场,未来竞争可能会加剧。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Scleroderma

      2. 4.2.2 Raised Focus of Pharmaceutical Companies to Come up With Novel Drugs

    3. 4.3 Market Restraints

      1. 4.3.1 Regulatory and Reimbursement Issues

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Disease Type

      1. 5.1.1 Systemic Scleroderma

      2. 5.1.2 Localized Scleroderma

    2. 5.2 By Drug Type

      1. 5.2.1 Phosphodiesterase 5 inhibitors - PHA

      2. 5.2.2 Prostacyclin Analogues

      3. 5.2.3 Immunosuppressors

      4. 5.2.4 Endothelin Receptor Antagonists

      5. 5.2.5 Calcium Channel Blockers

      6. 5.2.6 Other Drug Types

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Boehringer Ingelheim International GmbH

      2. 6.1.2 Celgene Corporation

      3. 6.1.3 arGentis Pharmaceuticals LLC

      4. 6.1.4 Prometic Life Sciences Inc.

      5. 6.1.5 Kadmon Holdings Inc.

      6. 6.1.6 Emerald Health Pharmaceuticals

      7. 6.1.7 Cytori Therapeutics Inc.

      8. 6.1.8 Chemomab

      9. 6.1.9 Corbus Pharmaceuticals Holdings Inc.

      10. 6.1.10 Bayer AG

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Scleroderma Therapeutics Market market is studied from 2018 - 2026.

The Scleroderma Therapeutics Market is growing at a CAGR of 5.7% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Boehringer Ingelheim International GmbH, Celgene Corporation, arGentis Pharmaceuticals Llc, Kadmon Holdings, Inc., Emerald Health Pharmaceuticals are the major companies operating in Scleroderma Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!